These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1436703)

  • 21. CCK receptors and human neurological disease.
    Hays SE; Paul SM
    Life Sci; 1982 Jul; 31(4):319-22. PubMed ID: 6292647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
    Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
    Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease.
    Ellison DW; Beal MF; Martin JB
    Brain Res; 1987 Aug; 417(2):389-92. PubMed ID: 2958109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
    Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
    Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
    Guidetti P; Bates GP; Graham RK; Hayden MR; Leavitt BR; MacDonald ME; Slow EJ; Wheeler VC; Woodman B; Schwarcz R
    Neurobiol Dis; 2006 Jul; 23(1):190-7. PubMed ID: 16697652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
    Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
    Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease.
    Beal MF; Benoit R; Bird ED; Martin JB
    Neurosci Lett; 1985 May; 56(3):377-80. PubMed ID: 2862613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease.
    Passani LA; Vonsattel JP; Coyle JT
    Brain Res; 1997 Oct; 772(1-2):9-22. PubMed ID: 9406950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Huntington's disease and neurotoxins.
    Martin JB; Beal MF
    Ann N Y Acad Sci; 1992 May; 648():169-75. PubMed ID: 1386201
    [No Abstract]   [Full Text] [Related]  

  • 30. 3-Hydroxykynurenine toxicity on the rat striatum in vivo.
    Nakagami Y; Saito H; Katsuki H
    Jpn J Pharmacol; 1996 Jun; 71(2):183-6. PubMed ID: 8835646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased concentrations of 3-hydroxykynurenine in vitamin B6 deficient neonatal rat brain.
    Guilarte TR; Wagner HN
    J Neurochem; 1987 Dec; 49(6):1918-26. PubMed ID: 3681302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of mitochondrial toxins on the brain amino acid concentrations.
    Klivenyi P; Kekesi KA; Hartai Z; Juhasz G; Vecsei L
    Neurochem Res; 2005 Nov; 30(11):1421-7. PubMed ID: 16341939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
    Rossor M; Emson P; Dawbarn D; Dockray G; Mountjoy C; Roth M
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():259-77. PubMed ID: 2425405
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma choline and cholinergic mechanisms in the brain. Methods, function, and rôle in Huntington's chorea.
    Eckernäs SA
    Acta Physiol Scand Suppl; 1977; 449():1-62. PubMed ID: 143869
    [No Abstract]   [Full Text] [Related]  

  • 35. Disease-related protein changes in purified neurons from Alzheimer's and Huntington's diseases.
    Selkoe DJ
    Trans Am Neurol Assoc; 1979; 104():70-4. PubMed ID: 162259
    [No Abstract]   [Full Text] [Related]  

  • 36. Kynurenines impair energy metabolism in rat cerebral cortex.
    Schuck PF; Tonin A; da Costa Ferreira G; Viegas CM; Latini A; Duval Wannmacher CM; de Souza Wyse AT; Dutra-Filho CS; Wajner M
    Cell Mol Neurobiol; 2007 Feb; 27(1):147-60. PubMed ID: 17151944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central kynurenine pathway shift with age in women.
    de Bie J; Guest J; Guillemin GJ; Grant R
    J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Striatal neural grafting improves cortical metabolism in Huntington's disease patients.
    Gaura V; Bachoud-Lévi AC; Ribeiro MJ; Nguyen JP; Frouin V; Baudic S; Brugières P; Mangin JF; Boissé MF; Palfi S; Cesaro P; Samson Y; Hantraye P; Peschanski M; Remy P
    Brain; 2004 Jan; 127(Pt 1):65-72. PubMed ID: 14607797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.